Single tRNA Molecule Found to Steer Prostate Cancer Between Drug Sensitivity and Resistance

SEATTLE — In a discovery that upends decades of assumptions about how cells regulate their own identity, researchers at Fred Hutch Cancer Center have shown that a single transfer RNA molecule can determine whether prostate cancer cells remain vulnerable to standard therapies or slip into an aggressive, drug-resistant state. The study, published October 7 in the journal Nature, is the first to demonstrate that an individual tRNA can actively control the identity of cancer cells, rather than serving as a passive workhorse of protein assembly. The finding suggests a fundamentally new strategy for reversing treatment resistance in prostate cancer, and potentially in other malignancies that undergo similar shifts in cellular character after therapy.

Transfer RNAs have long occupied a quiet corner of molecular biology. These small RNA molecules perform one of the most essential tasks in every living cell: during mRNA translation, they read the genetic instructions carried by messenger RNA and deliver the corresponding amino acids, which are then linked together to build proteins. Because every cell needs its proteins made, tRNAs were historically viewed as housekeeping components — abundant, interchangeable, and largely indifferent to the specific fate of the cell they serve. The new research challenges that view at its foundation. “The discovery opens an entirely new realm of cancer biology that was previously unrecognized,” said Andrew Hsieh, MD, co-corresponding author of the study and a professor and associate director of Fred Hutch’s Human Biology Division. “Historically, tRNAs have been thought to play a bystander role in cell maintenance and disease, but our study shows that tRNAs can actively shape the identity of cancer cells.”

The clinical backdrop for the work is one of the most common and consequential problems in oncology. Prostate cancer is a leading cause of cancer in men, and in its early stages it is typically driven by the androgen receptor, a protein that responds to male hormones and fuels tumor growth. Because of this dependence, the androgen receptor has long been the primary target of standard prostate cancer therapies, and drugs that block its activity are often effective initially. But many tumors do not stay vulnerable. Over time, a substantial fraction of prostate cancers undergo a profound change in cellular identity, shifting to an androgen receptor-independent state in which they no longer rely on the protein that the therapies were designed to suppress. Once tumors make this transition, they become more aggressive, less responsive to treatment, and considerably harder to manage.

Understanding what drives this identity switch has been a central question in prostate cancer research. Scientists have known that genomic mutations and alterations in transcription factor-driven gene expression — changes in which genes are switched on and off — accumulate during cancer progression and can contribute to the emergence of treatment resistance. But Yeon Soo Kim, PhD, first author of the Nature paper and a postdoctoral researcher in Hsieh’s laboratory at Fred Hutch, wanted to probe a layer of regulation that had received far less attention. “We already knew that genomic mutations or transcriptional factor-dependent genetic expression are altered during the cancer progression and can lead to the development of treatment resistance,” Kim explained. “But we wanted to know more about how mRNA translation — also known as protein synthesis — is involved when the disease becomes more aggressive.” Kim’s work on the project was supported by a National Cancer Institute K99/R00 Pathway to Independence Award, a prestigious grant designed to help promising early-career scientists launch independent research careers.

Kim focused on a specific step in the translation process: the moment when a tRNA molecule reads the biological information encoded in a messenger RNA and delivers the amino acid that it carries, allowing amino acids to be joined into a growing protein chain. It is a step that happens billions of times in every cell, and it depends on a large family of tRNAs, each tuned to recognize particular codons and deliver particular amino acids. Rather than treating this machinery as uniform background noise, Kim and her colleagues asked whether individual tRNAs might be differentially deployed as prostate cancer cells change their identity — and whether those differences might matter.

To answer that question, the team assembled evidence across multiple model systems. They examined prostate cancer cell lines grown in the laboratory, mouse models of the disease, and tumor samples taken from patients. Across all of these systems, a consistent pattern emerged. A specific transfer RNA, known as tRNA1Arg(UCU), was present at high levels in androgen receptor-dependent prostate cancer cells — the treatment-sensitive state — but was markedly diminished in tumors that had become less dependent on the androgen receptor and resistant to therapy. The consistency of the pattern across cell lines, animal models and human tissue suggested that the tRNA was not an incidental byproduct of disease progression but a feature closely tied to the cancer’s state.

The most striking result came from the next set of experiments, which tested whether the correlation ran in a causal direction. When the researchers supplied the specific tRNA to treatment-resistant tumors, the tumors reverted to a state in which they were once again sensitive to therapies targeting the androgen receptor. In other words, restoring a single RNA molecule appeared to push aggressive, drug-resistant cancer cells back toward the vulnerable identity they had abandoned. “We found that we can shift the cell state between androgen receptor-dependent to an androgen receptor-independent state with a single tRNA,” Kim said. “This is important because changes in cell identity are a major reason prostate cancers become resistant to treatment. We found that this tRNA can influence whether cells remain in a drug-sensitive state or transition to one that is more aggressive.”

The implications extend well beyond the prostate. Changes in cellular identity — sometimes described as lineage plasticity — are increasingly recognized as a common route by which cancers evade targeted therapies across many tumor types. Lung cancers and breast cancers, among others, are known to undergo identity switches after treatment, allowing them to survive in forms that existing drugs no longer recognize. “In this study we used prostate cancer as an archetype to study tRNA dependent state changes, but we think it’s just the beginning,” said Kim, who plans to pursue this line of research when she establishes her own laboratory. “We can apply this approach to any type of disease models or other types of cancers that undergo identity switches after treatment, such as lung and breast cancers.” If tRNA dosage proves to be a general lever for controlling cell state, it could open a new chapter in precision oncology, one in which the translation machinery itself becomes a therapeutic target.

Kim and Hsieh are already exploring how the tRNA could be harnessed in the clinic, both as a biomarker and as a therapeutic target for aggressive prostate cancer. As a biomarker, measuring levels of tRNA1Arg(UCU) in tumor samples could potentially help clinicians determine whether a patient’s cancer remains dependent on the androgen receptor and therefore likely to respond to receptor-targeted therapies, guiding more precise treatment decisions. As a therapeutic target, the finding raises the possibility of developing interventions that restore or mimic the tRNA’s activity in resistant tumors, effectively reversing resistance rather than simply escalating treatment. Microscopy work published alongside the study illustrates the principle visually: human prostate cancer tissue with high amounts of the tRNA, revealed by dark purple and pink staining, was associated with tumors that depended on the androgen receptor for growth and were sensitive to therapies aimed at it.

The research was a collaborative effort spanning institutions. Co-corresponding author Tao Pan, PhD, of the University of Chicago brought expertise in tRNA biology to the project, and Hsieh — who holds the Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch and is also a professor in the Division of Hematology and Oncology at the University of Washington School of Medicine — contributed his laboratory’s focus on translation control in cancer. The study was funded by multiple grants from the National Institutes of Health, including the Pacific Northwest Prostate Cancer SPORE, and by the U.S. Department of Defense, with additional funding from the Prostate Cancer Foundation and the American Cancer Society. For a field that has long treated tRNAs as anonymous couriers, the message of the new work is hard to ignore: the machinery of protein synthesis may hold keys to cancer’s identity, and with them, new ways to unlock drug resistance.

Subject of Research: tRNA-mediated regulation of cell identity and drug resistance in prostate cancer

Article Title: Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance

Article References: Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, transfer RNA, tRNA1Arg(UCU), androgen receptor, drug resistance, mRNA translation, protein synthesis, cell identity, Fred Hutch Cancer Center, Nature, precision oncology, lineage plasticity